X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (19) 19
index medicus (18) 18
aged (14) 14
humans (14) 14
female (13) 13
mortality (10) 10
aged, 80 and over (9) 9
middle aged (8) 8
diabetes (7) 7
italy - epidemiology (7) 7
neurosciences (7) 7
pharmacology & pharmacy (7) 7
animals (6) 6
cardiac & cardiovascular systems (6) 6
medial prefrontal cortex (6) 6
prevention (6) 6
rats (6) 6
dose-response relationship, drug (5) 5
endocrinology & metabolism (5) 5
hospitalization - statistics & numerical data (5) 5
prefrontal cortex - drug effects (5) 5
psychiatry (5) 5
risk factors (5) 5
serotonin antagonists - pharmacology (5) 5
cardiovascular (4) 4
diabetes mellitus (4) 4
diabetics (4) 4
drug therapy (4) 4
elderly (4) 4
excitatory amino acid antagonists - pharmacology (4) 4
fluorobenzenes - pharmacology (4) 4
glutamate nmda receptors (4) 4
incidence (4) 4
internal medicine (4) 4
medicine & public health (4) 4
mellitus (4) 4
metaanalysis (4) 4
older people (4) 4
piperazines - pharmacology (4) 4
piperidines - pharmacology (4) 4
reaction-time-task (4) 4
receptors (4) 4
receptors, n-methyl-d-aspartate - antagonists & inhibitors (4) 4
stroke (4) 4
treatment outcome (4) 4
5-ht (3) 3
5-ht2a receptors (3) 3
administrative database (3) 3
analysis (3) 3
analysis of variance (3) 3
atrial fibrillation (3) 3
attention (3) 3
attention - drug effects (3) 3
cardiovascular diseases - epidemiology (3) 3
cardiovascular diseases - prevention & control (3) 3
care and treatment (3) 3
cohort studies (3) 3
databases, factual (3) 3
diabetes mellitus - drug therapy (3) 3
epidemiology (3) 3
frontal-cortex (3) 3
general practice (3) 3
hypoglycemic agents (3) 3
hypoglycemic agents - therapeutic use (3) 3
italy (3) 3
logistic models (3) 3
management (3) 3
medical research (3) 3
medicine, experimental (3) 3
practice patterns, physicians (3) 3
prevalence (3) 3
rat (3) 3
reaction time - drug effects (3) 3
receptors, n-methyl-d-aspartate - physiology (3) 3
risk assessment (3) 3
risk-factors (3) 3
serotonin - metabolism (3) 3
time factors (3) 3
5-csrt task (2) 2
adherence (2) 2
adult (2) 2
adults (2) 2
antidiabetic drugs (2) 2
association (2) 2
atrial fibrillation - diagnosis (2) 2
atrial-fibrillation (2) 2
attention and executive functions (2) 2
behavior, animal (2) 2
behavior, animal - drug effects (2) 2
biomedicine (2) 2
cardiovascular diseases - diagnosis (2) 2
cardiovascular diseases - mortality (2) 2
complications and side effects (2) 2
coronary-heart-disease (2) 2
death (2) 2
diabetes mellitus - diagnosis (2) 2
diabetes mellitus - epidemiology (2) 2
diabetes mellitus - mortality (2) 2
diabetes therapy (2) 2
diabetic angiopathies - epidemiology (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ricerca e Pratica, ISSN 1120-379X, 11/2014, Volume 30, Issue 6, pp. 279 - 280
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 04/2006, Volume 31, Issue 4, pp. 757 - 767
Serotonin (5-HT) receptors are increasingly recognized as major targets for cognitive enhancement in schizophrenia. Several lines of evidence suggest a... 
Attention and executive functions | Medial prefrontal cortex (mPFC) | receptors | Rat | 5-HT | Glutamate NMDA receptors | glutamate NMDA receptors | 5-HT2A receptors | DORSAL-RAPHE | rat | DOPAMINE RELEASE | medial prefrontal cortex (mPFC) | PSYCHIATRY | FRONTAL-CORTEX | SEROTONIN RECEPTORS | NEUROSCIENCES | REACTION-TIME-TASK | GLUTAMATERGIC NEUROTRANSMISSION | IN-VIVO | attention and executive functions | ATTENTIONAL PERFORMANCE | PHARMACOLOGY & PHARMACY | 5-HT1A receptors | PRIMATE CEREBRAL-CORTEX | WORKING-MEMORY | Male | Impulsive Behavior - physiopathology | Serotonin Receptor Agonists - pharmacology | Behavior, Animal | Dose-Response Relationship, Drug | Fluorobenzenes - pharmacology | Attention - physiology | Drug Interactions | Prefrontal Cortex - drug effects | Piperidines - pharmacology | Reaction Time - drug effects | Attention - drug effects | Compulsive Behavior - physiopathology | Choice Behavior - physiology | Choice Behavior - drug effects | Rats | Receptor, Serotonin, 5-HT1A - physiology | Excitatory Amino Acid Antagonists - pharmacology | 8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology | Serotonin Antagonists - pharmacology | Piperazines - pharmacology | Receptors, N-Methyl-D-Aspartate - physiology | Receptor, Serotonin, 5-HT2A - physiology | Animals | Analysis of Variance | Pyridines - pharmacology | Prefrontal Cortex - physiology
Journal Article
Journal Article
Psychopharmacology, ISSN 0033-3158, 2/2008, Volume 196, Issue 2, pp. 269 - 280
Cognitive impairment in schizophrenia is particularly evident in the domains of attention and executive functions. Atypical antipsychotics are somewhat more... 
Serotonin 5-HT 2A receptors | Rat | Attention | Haloperidol | Clozapine | Prefrontal cortex | Glutamate NMDA receptors | Antipsychotics | Biomedicine | Dopamine D 2 receptors | Response control | Pharmacology/Toxicology | Psychiatry | receptors | Serotonin 5-HT | Dopamine D | IN-VIVO OCCUPANCY | glutamate NMDA receptors | rat | DOPAMINE RELEASE | PREPULSE INHIBITION | PSYCHIATRY | prefrontal cortex | NEUROCOGNITIVE DEFICITS | serotonin 5-HT2A receptors | NEUROSCIENCES | dopamine D-2 receptors | REACTION-TIME-TASK | PHENCYCLIDINE-INDUCED DEFICITS | NUCLEUS-ACCUMBENS | ATYPICAL ANTIPSYCHOTIC-DRUGS | haloperidol | DOUBLE-BLIND TRIAL | antipsychotics | MEDIAL PREFRONTAL CORTEX | clozapine | attention | PHARMACOLOGY & PHARMACY | response control | Piperazines - administration & dosage | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Schizophrenia - metabolism | Serotonin Antagonists - administration & dosage | Clozapine - administration & dosage | Haloperidol - administration & dosage | Male | Piperazines - toxicity | Dopamine Antagonists - administration & dosage | Dose-Response Relationship, Drug | Clozapine - pharmacology | Prefrontal Cortex - drug effects | Schizophrenia - physiopathology | Reaction Time - drug effects | Attention - drug effects | Behavior, Animal - drug effects | Serial Learning - drug effects | Haloperidol - pharmacology | Schizophrenia - chemically induced | Microinjections | Injections, Intraperitoneal | Rats | Serotonin Antagonists - pharmacology | Antipsychotic Agents - administration & dosage | Animals | Analysis of Variance | Dopamine Antagonists - pharmacology | Prefrontal Cortex - metabolism | Antipsychotic Agents - pharmacology | Psychotropic drugs | Animal behavior | Rodents | Schizophrenia | Pharmacology | Drug therapy | Animal cognition
Journal Article
NEUROPSYCHOPHARMACOLOGY, ISSN 0893-133X, 09/2004, Volume 29, Issue 9, pp. 1637 - 1647
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 11/2018, Volume 25, Issue 16, pp. 1735 - 1743
Background The aim of our study was to evaluate whether treatments for peripheral artery disease changed in two different cohorts identified in 2002 and 2008,... 
mortality | Peripheral arterial disease | cardio-cerebrovascular events | revascularization | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | RAMIPRIL | CORONARY | PREVENTION
Journal Article
Journal Article
BMC PEDIATRICS, ISSN 1471-2431, 05/2019, Volume 19, Issue 1, pp. 140 - 140
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 07/2016, Volume 18, Issue 7, pp. 840 - 848
Aims Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently co‐exist, and each is a major public health issue. In a large cohort of... 
Heart failure | Chronic obstructive pulmonary disease | Treatment | Epidemiology | Outcome | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | 30-DAY READMISSION | EUROPEAN-SOCIETY | ATRIAL-FIBRILLATION | TRIAL | EJECTION FRACTION | SYSTOLIC DYSFUNCTION | BETA-BLOCKERS | ADMINISTRATIVE DATABASE | Bronchodilator Agents - therapeutic use | Multivariate Analysis | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Male | Nitrates | Xanthines - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Heart Failure - therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aged, 80 and over | Female | Cardiac Resynchronization Therapy | Adrenergic beta-Antagonists - therapeutic use | Heart Failure - complications | Hypolipidemic Agents | Mortality | Information Storage and Retrieval | Proportional Hazards Models | Anticoagulants - therapeutic use | Treatment Outcome | Hospitalization | Anti-Arrhythmia Agents - therapeutic use | Pulmonary Disease, Chronic Obstructive - complications | Mineralocorticoid Receptor Antagonists - therapeutic use | Adrenergic beta-Agonists | Cholinergic Antagonists | Digitalis Glycosides | Platelet Aggregation Inhibitors | Diuretics - therapeutic use | Aged | Patient Readmission - statistics & numerical data | Angiotensin Receptor Antagonists - therapeutic use | Cohort Studies | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Journal Article